Login to Your Account



Achillion Closes $41M Round, Plans Phase III Trials This Year

By Karen Young


Tuesday, January 29, 2002
Achillion Pharmaceuticals Inc. raised $41 million in a private round of financing that its CEO expects will allow it to take its lead anti-infective compound through Phase II trials and into Phase III before year’s end.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription